Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : What is a COVID-19 vaccine 'breakthrough' case?

07/29/2021 | 12:06am EDT

What is a COVID-19 vaccine “breakthrough” case?

It’s when a fully vaccinated person gets infected with the coronavirus.

In studies, the two-dose COVID-19 vaccines by Pfizer and Moderna were around 95% effective at preventing illness, while the one-shot Johnson & Johnson shot was 72% effective, though direct comparisons are difficult. So while the vaccines are very good at protecting us from the virus, it’s still possible to get infected with mild or no symptoms, or even to get very sick.

If you do end up getting sick despite vaccination, experts say the shots help reduce the severity of the illness — the main reason to get vaccinated.

But the understanding of how vaccinated people who are infected might spread the virus to others is changing.

Previously, health officials believed vaccinated people who get breakthrough infections were unlikely to spread the virus. But with the more contagious delta variant that is now dominant, the U.S. Centers for Disease Control and Prevention said new data shows people who get infected could carry enough virus in their noses and throats to spread it to others.

The agency recently cited the data in updating its guidance to say vaccinated people should go back to wearing masks indoors in areas where the virus is surging.

“It is concerning enough that we feel like we have to act,” said CDC Director Dr. Rochelle Walensky.

Still, health experts say the vaccines provide strong protection against serious illness. In the U.S., people who weren’t vaccinated make up nearly all hospitalizations and deaths from COVID-19.

The AP is answering your questions about the coronavirus in this series. Submit them at: FactCheck@AP.org. Read more here:

Should vaccinated people mask up with COVID-19 cases rising?

What should I know about the delta variant?

Can you mix and match two-dose COVID-19 vaccines?

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about JOHNSON & JOHNSON
09/22JOHNSON & JOHNSON : Unit Signs Deal for HealthVerity Patient Data Platform
MT
09/22PRO BANKRUPTCY BRIEFING : J&J Beats Injury Lawyers on Talc Bankruptcy; Judge Questions Tal..
DJ
09/21JOHNSON & JOHNSON : Unit Collaborates With Persephone Biosciences On Stool Analysis
MT
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21Johnson & Johnson Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to S..
MT
09/21Today on Wall Street: Markets at a pivot point
09/21JOHNSON & JOHNSON : Says New Data Show Booster Shot Increases COVID-19 Protection
MT
09/21J&J : Booster dose of its COVID shot prompts strong response
AQ
09/21JOHNSON & JOHNSON : Says New Data Shows a Booster of its One-Shot Vaccine Increases COVID-..
MT
09/21JOHNSON & JOHNSON : Announces Real-World Evidence and Phase 3 Data Confirming Strong and L..
PR
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,0x
Yield 2021 2,54%
Capitalization 432 B 432 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,38x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,93 $
Average target price 185,83 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972
ABBVIE INC.-0.69%188 045